Zhejiang Taimei Medical Technology (2576) Fundamentals 2026 — Revenue Analysis | SniperIQ
Zhejiang Taimei Medical Technology (2576) is a CN-listed Technology company in Software - Application with a market capitalization of HK
Zhejiang Taimei Medical Technology (2576) has a market capitalization of approximately HK
Zhejiang Taimei Medical Technology's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 2.4x. Valuation multiples are best compared with Technology sector peers rather than read in isolation.
Zhejiang Taimei Medical Technology runs a net profit margin of -7.5%, a gross margin of 43.7%, and an operating margin of -13.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Zhejiang Taimei Medical Technology reported revenue of ¥499M for fiscal year 2025, with net income of -¥42M and earnings per share (EPS) of -0.074. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Zhejiang Taimei Medical Technology does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Zhejiang Taimei Medical Technology carries a debt-to-equity ratio of 0.05x and a current ratio of 4.48x, with a market beta of 0.32. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Zhejiang Taimei Medical Technology (2576) the key facts are: market cap HK
Get Zhejiang Taimei Medical Technology's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.